- Report
- January 2025
- 175 Pages
Global
From €4070EUR$4,490USD£3,521GBP
- Report
- July 2025
- 175 Pages
Global
From €4070EUR$4,490USD£3,521GBP
- Report
- August 2025
- 50 Pages
Global
From €2402EUR$2,650USD£2,078GBP
- Report
- August 2025
- 50 Pages
Global
From €2402EUR$2,650USD£2,078GBP
- Report
- May 2025
- 194 Pages
Global
From €3214EUR$3,545USD£2,780GBP
€3571EUR$3,939USD£3,089GBP
- Report
- March 2025
- 200 Pages
Global
From €4070EUR$4,490USD£3,521GBP
- Report
- July 2025
- 175 Pages
Global
From €4070EUR$4,490USD£3,521GBP
- Report
- March 2025
- 200 Pages
Global
From €4070EUR$4,490USD£3,521GBP
- Report
- January 2025
- 175 Pages
Global
From €4070EUR$4,490USD£3,521GBP
- Report
- August 2025
- 282 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2720EUR$3,000USD£2,353GBP
- Report
- September 2024
- 343 Pages
Global
From €7207EUR$7,950USD£6,235GBP
- Report
- May 2025
- 196 Pages
Global
From €4306EUR$4,750USD£3,725GBP
- Report
- March 2025
- 84 Pages
Global
From €3500EUR$4,136USD£3,134GBP
- Report
- January 2023
- 130 Pages
Global
From €5394EUR$5,950USD£4,666GBP
- Report
- May 2024
- 182 Pages
Global
From €4080EUR$4,500USD£3,529GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3400EUR$3,750USD£2,941GBP
- Report
- July 2024
- 150 Pages
Global
From €3400EUR$3,750USD£2,941GBP
- Report
- January 2024
- 125 Pages
Global
From €7207EUR$7,950USD£6,235GBP
- Report
- March 2023
- 147 Pages
Global
From €4487EUR$4,949USD£3,881GBP

Albuterol is a medication used to treat and prevent bronchospasm in people with asthma, chronic obstructive pulmonary disease (COPD), and other breathing disorders. It is a short-acting β2-adrenergic receptor agonist, which works by relaxing the muscles of the airways and increasing airflow to the lungs. Albuterol is available in both oral and inhaled forms, and is often used in combination with other medications to treat respiratory conditions.
Albuterol is one of the most commonly prescribed respiratory drugs, and is widely used in both the United States and Europe. It is available in both generic and brand-name formulations, and is often used in combination with other medications to treat asthma and COPD. In addition, albuterol is used to treat acute exacerbations of COPD, and is also used to prevent exercise-induced bronchospasm.
Some companies in the Albuterol market include GlaxoSmithKline, Merck, Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more